Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathways Clear all
Recruiting Not applicable Interventional

Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways

NCT07469384
View directory record Official record
Conditions
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Interventions
transcranial direct current stimulation, Sham stimulation
Device
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Not applicable Interventional

Neural Correlates of Auriculotherapy

NCT06358287
View directory record Official record
Conditions
Chronic Pain
Interventions
cryogenic auriculotherapy
Procedure
Lead sponsor
Keith M. Vogt, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional

Virtual Reality Therapy for Cancer-Treatment Associated Symptoms

NCT06248216
View directory record Official record
Conditions
Cancer, Cancer Pain, Virtual Reality
Interventions
Relievrx, Audio Mp4
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

TrialNet Pathway to Prevention of T1D

NCT00097292
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 45 Years
Enrollment
75,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2030
U.S. locations
17
States / cities
Orange, California • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 17, 2026, 6:50 PM EDT
Active, not recruiting Not applicable Interventional

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

NCT02735252
View directory record Official record
Conditions
Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
Interventions
Systemic therapy, StrataNGS
Other · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 17, 2026, 6:50 PM EDT
Terminated Phase 1 Interventional

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

NCT02476955
View directory record Official record
Conditions
Solid Tumors, Ovarian Cancer, Endometrial Cancer
Interventions
ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Phase 1 Interventional

CC-486 and Venetoclax for Acute Myeloid Leukemia

NCT05287568
View directory record Official record
Conditions
AML
Interventions
Venetoclax, CC-486
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Not applicable Interventional

Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

NCT03176485
View directory record Official record
Conditions
Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Metastatic Melanoma, HCC, Metastatic Colon Cancer
Interventions
Solar Simulator
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 17, 2026, 6:50 PM EDT
Terminated Phase 1 Interventional

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

NCT04417517
View directory record Official record
Conditions
Higher Risk Myelodysplastic Syndromes
Interventions
evorpacept, azacitidine
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

NCT07560813
View directory record Official record
Conditions
Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions
Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs
Dietary Supplement · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Withdrawn Phase 1 Interventional

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

NCT01236586
View directory record Official record
Conditions
Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma, Wilm's Tumor
Interventions
RO4929097, Dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Bethesda, Maryland • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Improving the Management of Acute Coronary Syndromes in the Emergency Department

NCT01563250
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Point of Care testing
Device
Lead sponsor
Integrated Medical Research LLC
Other
Eligibility
35 Years and older
Enrollment
705 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

NCT01132664
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2+ Breast Cancer
Interventions
BKM120, Trastuzumab, Capecitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Not applicable Interventional

MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning

NCT01534104
View directory record Official record
Conditions
Brain Cancer
Interventions
preoperative fMRI. DTI and DSI with tractography
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

NCT05736367
View directory record Official record
Conditions
Breast Cancer
Interventions
U-13C-glucose
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness

NCT06203509
View directory record Official record
Conditions
Care Transitions
Interventions
Thrive Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional

Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway

NCT07175376
View directory record Official record
Conditions
Cancer, Frail, Chemotherapy
Interventions
Supportive Care
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting No phase listed Observational

Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System

NCT07223489
View directory record Official record
Conditions
Spinal Muscular Atrophy (SMA)
Interventions
Telephone Interview
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washinton, District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

NIMH Clinical Pathway in Rural Appalachian School-based Health Clinics

NCT06808503
View directory record Official record
Conditions
Suicide Prevention, Suicide
Interventions
NIMH Clinical Pathway
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
12 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Morgantown, West Virginia • Oak Hill, West Virginia • Summersville, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Not applicable Interventional

Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.

NCT00778960
View directory record Official record
Conditions
Post-Traumatic Stress Disorders
Interventions
Slow Breathing, Meditation, Meditation and slow breathing, Sitting Quietly
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
25 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Not applicable Interventional Results available

The Cascade Feasibility Pilot (Ileostomy)

NCT05048329
View directory record Official record
Conditions
Ileostomy; Complications, Ileostomy - Stoma
Interventions
Non-invasive continuous remote monitoring with structured escalation pathway, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Evanston, Illinois • Glenview, Illinois • Highland Park, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 17, 2026, 6:50 PM EDT
Completed No phase listed Observational

Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

NCT02849977
View directory record Official record
Conditions
Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations
Interventions
Not listed
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
5,966 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 17, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

NCT03433183
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
Interventions
Selumetinib, Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 17, 2026, 6:50 PM EDT